A phase 2 study of tafasitamab for treatment of Relapsed or refractory Chronic lymphocytic leukemia
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Tafasitamab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms coreMIND
- 11 Nov 2021 New trial record